A late-stage trial of retatrutide showed large weight loss in type 2 diabetes
In an 80-week trial of 1,152 adults with obesity and type 2 diabetes, the highest dose of the experimental drug retatrutide cut weight more than placebo and lowered HbA1c. It is not FDA-approved.
Read the original
The reporting lives at Medical Xpress. Our summary is checked against it, and we link it on every story.
Medical Xpress reported results from The Lancet on TRIUMPH-2, an 80-week Phase 3 trial of 1,152 adults who had obesity and type 2 diabetes. At the highest dose, Eli Lilly's experimental weekly injection, retatrutide, was associated with an average weight loss of 18.8 percent, compared with 5.1 percent for people who received a placebo. Hemoglobin A1c, a longer-term measure of blood sugar, was about 1.5 points lower.
The drug is still experimental. It is not approved by the Food and Drug Administration, and this trial is not a decision that it will be. Gastrointestinal side effects were common. The study does not show that retatrutide cures diabetes, and it does not replace care a person already has. A clinician is the right person to talk with about treatments that are already approved.
More good news
Other stories in the same neighborhood of kindness.
CommunityFrench Lick's Pumpkin Festival handed kids free ride bracelets
Orange County's 58th Pumpkin Festival was free to enter, and for the fifth year children could get bracelets for the rides. Organizer Dustin Farris said a local carnival is the big trip many kids get.
Verified · Indiana Public Media
Health & TechThe FDA approved the first disease-modifying drug for Alexander disease
Zanvastro (zilganersen) is approved for a rare, often fatal brain disorder. In a controlled trial, treated patients 5 and older with walking trouble were faster at 61 weeks, and treated 2- to 4-year-olds gained motor skills while untreated children declined. It is not a cure.
Verified · Nature Biotechnology
Health & TechThe FDA approved a once-monthly olanzapine injection for schizophrenia
On October 9 the FDA approved Teva's Weltruza, a long-acting injection for adults with schizophrenia. Teva expects a U.S. launch within weeks. It is not a cure.
Verified · CNBC